2019 CSCO | CStone announces preliminary results from Phase I trial of CS1002 demonstrating characteristics comparable to ipilimumab

SUZHOU, China, Sept. 21, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced preliminary results from the Phase Ia trial of the Company's anti-CTLA-4 antibody in an oral presentation at the 22nd Annual Meeting of the Chinese Society of...

from PR Newswire: https://ift.tt/30AG5uN